Drug Profile
Radgocitabine - Delta-Fly Pharma
Alternative Names: CNDAC; DFP-10917; NS 917; TAS-109Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Delta-Fly Pharma
- Developer Delta-Fly Pharma; Nippon Shinyaku
- Class Amines; Antineoplastics; Nitriles; Pyrimidines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 08 Mar 2024 Delta Fly Pharma had submitted the protocol to FDA of the phase I/II study of DFP 10917 combined with Venetoclax (VTX) in acute myeloid leukemia
- 07 Jan 2024 Delta Fly Pharma has patent protection for combination therapy of radgocitabine and venetoclax in Acute myeloid leukaemia the US, Japan and Taiwan
- 07 Jan 2024 Delta-Fly Pharma plans a phase I/II trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)